ArticleFrontiers in oncology2025
Development of a prediction model for pulmonary nodules using circulating tumor cells combined with the uAI platform.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in modelling the risk of benign and malignant lung nodules.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the clinical application value of combining circulating tumor cell (CTC) detection with the artificial intelligence imaging software "uAI platform" in predicting the pathological nature of pulmonary nodules (PN). Develop a joint diagnostic system based on the uAI platform and quantitative detection of CTCs, enable simultaneous classification of pulmonary nodules as benign or malignant and assess the degree of infiltration. Methods: A total of 76 patients with pulmonary nodules undergoing surgical treatment were enrolled. Preoperatively, three-dimensional nodule risk stratification (low、medium、high risk) was performed using the uAI platform, and CTC high-throughput detection was conducted. Key indicators were selected through multi-group comparisons (Benign、Malignant、Invasive subgroups) and logistic regression analysis. A multi-dimensional nomogram model was constructed, and its clinical utility was evaluated using ROC curves and clinical decision curves. Results: Comparison between benign and malignant pulmonary nodule groups revealed significant differences in the risk stratification of the uAI platform (proportion of high-risk: 75.61% Conclusion: The combined uAI-CTC model breaks through the limitations of single-dimension diagnosis, enabling risk stratification of malignant pulmonary nodules and quantitative assessment of infiltration, providing evidence-based support for clinical treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.